Management of Non-Alcholic Fatty Liver Disease.
- Conditions
- Health Condition 1: K77- Liver disorders in diseases classified elsewhere
- Registration Number
- CTRI/2023/05/053015
- Lead Sponsor
- ITRA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients will be diagnosed on the basis of following signs and symptoms:
Dyspepsia, Nausea, Malaise, Fatigue, feeling of fullness in the abdomen, Generalized
weakness, Upper abdominal pain and discomfort.
2.With or without
Blood â?? Elevated serum transaminases, Alkaline phosphatase.
Deranged lipid profile- S. Cholesterol, S. Triglyceride, S. HDL, S. LDL, S. VLDL
3.Both newly detected and previously diagnosed cases of Non-Alcoholic Fatty Liver Disease.
4.USG findings suggestive of fatty liver grade I & II.
5.Patients of Yakriddaalyudara (Non-Alcoholic Fatty Liver Disease) with controlled blood pressure ( >140/90 mm of hg) & Diabetic Mellitus (RBS 90-140 mg/dl).
1.Patient aged below 20 years and above 60 years, pregnant women.
2.Patients with uncontrolled Diabetes or Hypertension, Patients with complications of Metabolic syndrome like Cerebrovascular accident (CVA), Myocardial Infarction (MI), chronic kidney disease (CKD).
3.Patients suffering from GB stone or obstructive jaundice
4.Patients consuming Hepatotoxic medicines, Alcohol or other Narcotic substances.
5.Patients suffering from Cirrhosis, Ascites, variceal hemorrhage, Coagulopathy, Hepato-Renal Syndrome.
6.Patients having history of Viral hepatitis (HbsAg, HCV), Auto-immune liver diseases (Primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis), Metabolic disorders (Wilsonâ??s disease, haemochromatosis), congenital blood diseases (sickle cell disease, thalassemia, G6PD deficiency anemia etc.)
7.Patients suffering from HIV, TB other infectious diseases, Malignancies, major psychiatric problems or any other serious illnesses.
8.Hb% < 10 gm %
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relief in symptoms like Dyspepsia, Nausea, Malaise, Fatigue, the feeling of fullness in the abdomen, Generalized <br/ ><br>weakness, Upper abdominal pain, and discomfort.Timepoint: 2 Week
- Secondary Outcome Measures
Name Time Method Symptomatic relief like <br/ ><br> Dyspepsia, Nausea, Malaise, Fatigue, feeling of fullness in the abdomen, Generalized <br/ ><br>weakness, Upper abdominal pain and discomfort. <br/ ><br>2.laboratory parameter change like Liver Profile direct bilirubin and total bilirubin, S. Protein, S. Albumin, Albumin/Globulin ratio, SGOT, SGPT, S. Alkaline phosphatase, lipid profile- S. Cholesterol, S. Triglyceride, S. HDL, S. LDL, S. VLDL <br/ ><br>4.USG findingsTimepoint: Day 0 and Day 30